EUVIMEDEUVIMED entdecken
Open Access

In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus

Liang Chen iD, Elena Shashkina, Natalia Kurepina, Vinicius Calado Nogueira de Moura iD, Charles L Daley, Barry N Kreiswirth iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00174-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Liang Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Meropenem, Microbial Sensitivity Tests, Boronic Acids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium abscessus (MAB) infections pose a growing public health threat. Here, we assessed the in vitro activity of the boronic acid-based β-lactamase inhibitor, vaborbactam, with different β-lactams against 100 clinical MAB isolates. Enhanced activity was observed with meropenem and ceftaroline with vaborbactam (1- and >4-fold MIC 50 / 90 reduction). CRISPRi-mediated bla MAB gene knockdown showed a fourfold MIC reduction to ceftaroline but not the other β-lactams. Our findings demonstrate vaborbactam’s potential in combination therapy against MAB infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusMeropenemMicrobial Sensitivity TestsBoronic AcidsAnti-Bacterial AgentsCeftarolineCephalosporinsImipenemCefoxitinHumansMycobacterium Infections, Nontuberculousbeta-Lactamase Inhibitors

Stichwörter der Autor:innen

CRISPR interferenceMycobacterium abscessuspeptidoglycan synthesisvaborbactamβ-lactamase inhibitors

Substanzen

MeropenemBoronic AcidsAnti-Bacterial AgentsCeftarolinevaborbactamCephalosporinsImipenemCefoxitinbeta-Lactamase Inhibitors

Autor:innen und Institutionen

  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
  • Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
  • Department of Medicine, National Jewish Health, Denver, Colorado, USA.
  • The University of Colorado, Aurora, Colorado, USA.

ORCID-Profile: Liang Chen, Vinicius Calado Nogueira de Moura, Barry N Kreiswirth

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

Chen, L., Shashkina, E., Kurepina, N., Calado Nogueira de Moura, V., Daley, C. L., & Kreiswirth, B. N. (2024). In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00174-24

Vancouver

Chen L, Shashkina E, Kurepina N, Calado Nogueira de Moura V, Daley CL, Kreiswirth BN. In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00174-24

BibTeX
@article{Chen2024,
  author = {Chen, Liang and Shashkina, Elena and Kurepina, Natalia and Calado Nogueira de Moura, Vinicius and Daley, Charles L and Kreiswirth, Barry N},
  title = {In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00174-24}
}
Kostenlos starten →